Clinical carbapenem-resistant Klebsiella pneumoniae isolates simultaneously harboring bla NDM-1, bla OXA types and qnrS genes from the Kingdom of Bahrain: Resistance profile and genetic environment

The prevalence of Carbapenem-resistant Klebsiella pneumoniae (CRKP) is currently increasing worldwide, prompting WHO to classify it as an urgent public health threat. CRKP is considered a difficult to treat organism owing to limited therapeutic options. In this study, a total of 24 CRKP clinical isolates were randomly collected from Salmaniya Medical Complex, Bahrain. Bacterial identification and antibiotic susceptibility testing were performed, on MALDI-TOF and VITEK-2 compact, respectively. The isolates were screened for carbapenem resistance markers (bla NDM, bla OXA-23, bla OXA-48 and bla OXA-51) and plasmid-mediated quinolone resistance genes (qnrA, qnrB, and qnrS) by monoplex PCR. On the other hand, only colistin-resistant isolates (n=12) were screened for MCR-1, MCR-2 and MCR-3 genes by monoplex PCR. Moreover, the Genetic environment of bla NDM, integrons analysis, and molecular characterization of plasmids was also performed. Antibiotic susceptibility revealed that all the isolates (100%) were resistant to ceftolozane/tazobactam, piperacillin/tazobactam, 96% resistant to ceftazidime, trimethoprim/sulfamethoxazole, 92% resistant to meropenem, gentamicin and cefepime, 88% resistant to ciprofloxacin, imipenem, and 37% resistant to amikacin. Ceftazidime/avibactam showed the least resistance (12%). 75% (n=12/16) were resistant to colistin and 44% (n=7/16) showed intermediate susceptibility to tigecycline. The detection of resistant determinants showed that the majority (95.8%) of CRKP harbored bla NDM-1, followed by bla OXA-48 (91.6%) bla OXA-51 (45.8%), and bla OXA-23 (41.6%). Sequencing of the bla NDM amplicons revealed the presence of bla NDM-1. Alarmingly, 100% of isolates showed the presence of qnrS. These predominant genes were distributed in various combinations wherein the majority were bla NDM-1 + bla OXA-51+ qnrS + bla OXA-48 (n =10, 41.7%), bla NDM-1 + bla OXA-23+ qnrS + bla OXA-48 (n=8, 33.3%), among others. In conclusion, the resistance rate to most antibiotics is very high in our region, including colistin and tigecycline, and the genetic environment of CRKP is complex with the carriage of multiple resistance markers. Resistance to ceftazidime/avibactam is uncommon and hence can be used as a valuable option for empirical therapy. Molecular data on resistance markers and the genetic environment of CRKP is lacking from this geographical region; this would be the first report addressing the subject matter. Surveillance and strict infection control strategies should be reinforced in clinical settings to curb the emergence and spread of such isolates.

[1]  Nessma Hessin Mohamed Gandor,et al.  Characterization of Carbapenem-Resistant K. Pneumoniae Isolated from Intensive Care Units of Zagazig University Hospitals , 2022, Antibiotics.

[2]  J. Tanne Covid-19: Antimicrobial resistance rose dangerously in US during pandemic, CDC says , 2022, BMJ.

[3]  Samira Choudhury,et al.  Antimicrobial resistance and the COVID-19 pandemic , 2022, Bulletin of the World Health Organization.

[4]  M. Reis,et al.  Prolonged Outbreak of Carbapenem and Colistin-Resistant Klebsiella pneumoniae at a Large Tertiary Hospital in Brazil , 2022, Frontiers in Microbiology.

[5]  T. Banerjee,et al.  Extensive outbreak of colistin resistant, carbapenemase (blaOXA-48, blaNDM) producing Klebsiella pneumoniae in a large tertiary care hospital, India , 2022, Antimicrobial resistance and infection control.

[6]  F. Kolaylı,et al.  Molecular characterization of carbapenemase producing Klebsiella pneumoniae strains by multiplex PCR and PFGE methods: The first K.pneumoniae isolates co-producing OXA-48/KPC and KPC/NDM in Turkey. , 2021, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[7]  J. Rolain,et al.  Dissemination of Carbapenemases (OXA-48, NDM and VIM) Producing Enterobacteriaceae Isolated from the Mohamed VI University Hospital in Marrakech, Morocco , 2021, Antibiotics.

[8]  A. Ardebili,et al.  Molecular characteristics of antibiotic-resistant Escherichia coli and Klebsiella pneumoniae strains isolated from hospitalized patients in Tehran, Iran , 2020, Annals of clinical microbiology and antimicrobials.

[9]  S. Koo,et al.  Molecular epidemiology and mechanisms of tigecycline resistance in carbapenem‐resistant Klebsiella pneumoniae isolates , 2020, Journal of clinical laboratory analysis.

[10]  M. Castanheira,et al.  Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Comparators Tested Against Pseudomonas aeruginosa and Klebsiella pneumoniae Isolates from United States Medical Centers in 2016-2018. , 2020, Microbial drug resistance.

[11]  P. Aris,et al.  Molecular mechanisms and prevalence of colistin resistance of Klebsiella pneumoniae in the Middle East region: A review over five last years. , 2020, Journal of global antimicrobial resistance.

[12]  M. Shohayeb,et al.  The First Egyptian Report Showing the Co-Existence of blaNDM-25, blaOXA-23, blaOXA-181, and blaGES-1 Among Carbapenem-Resistant K. pneumoniae Clinical Isolates Genotyped by BOX-PCR , 2020, Infection and drug resistance.

[13]  O. Orole,et al.  Characterization and Plasmid Profile of Resistant Klebsiella pneumoniae Isolates in Patients with Urinary Tract Infection in Nasarawa State, Nigeria , 2020 .

[14]  K. Bush,et al.  Epidemiology of β-Lactamase-Producing Pathogens , 2020, Clinical Microbiology Reviews.

[15]  A. A. Elshamy,et al.  A review on bacterial resistance to carbapenems: epidemiology, detection and treatment options , 2020, Future science OA.

[16]  M. Beatty,et al.  Outbreak of colistin-resistant organisms at a tertiary hospital in Riyadh, Saudi Arabia, 2016 , 2019, The Pan African medical journal.

[17]  G. Peirano,et al.  The Global Ascendency of OXA-48-Type Carbapenemases , 2019, Clinical Microbiology Reviews.

[18]  B. Berglund Acquired Resistance to Colistin via Chromosomal And Plasmid-Mediated Mechanisms in Klebsiella pneumoniae , 2019, Infectious Microbes and Diseases.

[19]  J. Ahmad,et al.  Enterobacterial infection in Saudi Arabia: First record of Klebsiella pneumoniae with triple carbapenemase genes resistance. , 2019, Journal of infection in developing countries.

[20]  Mohammed A. Al-Biltagi,et al.  Epidemiology of carbapenem-resistant Enterobacteriaceae in a Tertiary Care Center in the Kingdom of Bahrain , 2019, Journal of laboratory physicians.

[21]  F. Hu,et al.  Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the In Vitro Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa , 2019, Antimicrobial Agents and Chemotherapy.

[22]  Rong Zhang,et al.  Tracking microevolution events among ST11 carbapenemase-producing hypervirulent Klebsiella pneumoniae outbreak strains , 2018, Emerging Microbes & Infections.

[23]  Hongwei Zhou,et al.  Evolution of tigecycline- and colistin-resistant CRKP (carbapenem-resistant Klebsiella pneumoniae) in vivo and its persistence in the GI tract , 2018, Emerging Microbes & Infections.

[24]  J. Lavigne,et al.  OXA-48-like carbapenemases producing Enterobacteriaceae in different niches , 2018, European Journal of Clinical Microbiology & Infectious Diseases.

[25]  Asad U. Khan,et al.  Occurrence of blaNDM Variants Among Enterobacteriaceae From a Neonatal Intensive Care Unit in a Northern India Hospital , 2018, Front. Microbiol..

[26]  E. Burd,et al.  Carbapenem-Resistant Klebsiella pneumoniae Exhibiting Clinically Undetected Colistin Heteroresistance Leads to Treatment Failure in a Murine Model of Infection , 2018, mBio.

[27]  I. Al-Zahrani,et al.  The emergence of carbapenem-resistant Klebsiella pneumoniae isolates producing OXA-48 and NDM in the Southern (Asir) province, Saudi Arabia , 2018, Saudi medical journal.

[28]  M. A. El-Feky,et al.  Co-occurrence of Plasmid-mediated Quinolone Resistance and Carbapenemases in Klebsiella pneumoniae Isolates in Assiut, Egypt , 2017 .

[29]  M. Bonilla,et al.  Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. , 2017, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[30]  D. van Duin,et al.  The global epidemiology of carbapenemase-producing Enterobacteriaceae , 2017, Virulence.

[31]  Asad U. Khan,et al.  Structure, Genetics and Worldwide Spread of New Delhi Metallo-β-lactamase (NDM): a threat to public health , 2017, BMC Microbiology.

[32]  Robert A. Weinstein,et al.  The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace , 2017, The Journal of infectious diseases.

[33]  Christina A. Sutherland,et al.  Potency of parenteral antimicrobials including ceftolozane/tazobactam against nosocomial respiratory tract pathogens: considerations for empiric and directed therapy. , 2017, Journal of thoracic disease.

[34]  S. Richter,et al.  Colistin Resistance in Carbapenem-Resistant Klebsiella pneumoniae , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  Min-Jeong Park,et al.  Prevalence and Molecular Characteristics of Carbapenemase-Producing Enterobacteriaceae From Five Hospitals in Korea , 2016, Annals of laboratory medicine.

[36]  Ronald N. Jones,et al.  Detection of mcr-1 among Escherichia coli Clinical Isolates Collected Worldwide as Part of the SENTRY Antimicrobial Surveillance Program in 2014 and 2015 , 2016, Antimicrobial Agents and Chemotherapy.

[37]  K. Kazmierczak,et al.  Global Dissemination of blaKPC into Bacterial Species beyond Klebsiella pneumoniae and In Vitro Susceptibility to Ceftazidime-Avibactam and Aztreonam-Avibactam , 2016, Antimicrobial Agents and Chemotherapy.

[38]  Y. Carmeli,et al.  The negative impact of antibiotic resistance. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[39]  M. Albert,et al.  High Prevalence of New Delhi Metallo-β-Lactamase-1 (NDM-1) Producers among Carbapenem-Resistant Enterobacteriaceae in Kuwait , 2016, PloS one.

[40]  H. Zhang,et al.  Outbreak of NDM-1-producing Klebsiella pneumoniae ST76 and ST37 isolates in neonates , 2016, European Journal of Clinical Microbiology & Infectious Diseases.

[41]  K. Bush A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. , 2015, International journal of antimicrobial agents.

[42]  P. Nordmann,et al.  Carbapenemase-Producing Klebsiella pneumoniae, a Key Pathogen Set for Global Nosocomial Dominance , 2015, Antimicrobial Agents and Chemotherapy.

[43]  Christina A. Sutherland,et al.  Susceptibility Profile of Ceftolozane/Tazobactam and Other Parenteral Antimicrobials Against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa From US Hospitals. , 2015, Clinical therapeutics.

[44]  V. Rotimi,et al.  Characterization of Carbapenem-Resistant Enterobacteriaceae with High Rate of Autochthonous Transmission in the Arabian Peninsula , 2015, PloS one.

[45]  F. Amer,et al.  Occurrence of classes I and II integrons in Enterobacteriaceae collected from Zagazig University Hospitals, Egypt , 2015, Front. Microbiol..

[46]  R. Valaperta,et al.  Emergence of Carbapenem-Resistant Klebsiella pneumoniae: Progressive Spread and Four-Year Period of Observation in a Cardiac Surgery Division , 2015, BioMed research international.

[47]  D. Hoban,et al.  In vitro activity of tigecycline and comparators against carbapenem-resistant Enterobacteriaceae in Africa-Middle East countries: TEST 2007-2012. , 2014, Journal of global antimicrobial resistance.

[48]  Tyson A. Clark,et al.  Whole-Genome Assembly of Klebsiella pneumoniae Coproducing NDM-1 and OXA-232 Carbapenemases Using Single-Molecule, Real-Time Sequencing , 2014, Antimicrobial Agents and Chemotherapy.

[49]  Ronald N. Jones,et al.  Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012). , 2014, International journal of antimicrobial agents.

[50]  Ronald N. Jones,et al.  Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012). , 2014, The Journal of antimicrobial chemotherapy.

[51]  Kui Zhang,et al.  Molecular characterization of clinical multidrug-resistant Klebsiella pneumoniae isolates , 2014, Annals of Clinical Microbiology and Antimicrobials.

[52]  Y. Yu,et al.  First description of NDM-1-, KPC-2-, VIM-2- and IMP-4-producing Klebsiella pneumoniae strains in a single Chinese teaching hospital , 2014, Epidemiology and Infection.

[53]  J. Karlowsky,et al.  Ceftazidime–avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections , 2014, Core evidence.

[54]  Z. Memish,et al.  The emergence of OXA-48- and NDM-1-positive Klebsiella pneumoniae in Riyadh, Saudi Arabia. , 2013, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[55]  Yongfei Hu,et al.  Structural Diversity of Class 1 Integrons and Their Associated Gene Cassettes in Klebsiella pneumoniae Isolates from a Hospital in China , 2013, PloS one.

[56]  R. Jureen,et al.  Emergence of Klebsiella pneumoniae co-producing NDM-type and OXA-181 carbapenemases. , 2013, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[57]  D. Paterson,et al.  β-Lactamase Production in Key Gram-Negative Pathogen Isolates from the Arabian Peninsula , 2013, Clinical Microbiology Reviews.

[58]  Xiaojiao Zhang,et al.  Prevalence of Plasmid-Mediated Quinolone Resistance and Aminoglycoside Resistance Determinants among Carbapeneme Non-Susceptible Enterobacter cloacae , 2012, PloS one.

[59]  Herman Goossens,et al.  Ready for a world without antibiotics? The Pensières Antibiotic Resistance Call to Action , 2012, Antimicrobial Resistance and Infection Control.

[60]  P. Nordmann,et al.  Emergence of OXA-48-Type Carbapenemase-Producing Enterobacteriaceae in German Hospitals , 2012, Antimicrobial Agents and Chemotherapy.

[61]  P. Nordmann,et al.  Association of the Emerging Carbapenemase NDM-1 with a Bleomycin Resistance Protein in Enterobacteriaceae and Acinetobacter baumannii , 2012, Antimicrobial Agents and Chemotherapy.

[62]  P. Nordmann,et al.  Emergence of NDM-1-producing Klebsiella pneumoniae in Morocco. , 2011, The Journal of antimicrobial chemotherapy.

[63]  P. Nordmann,et al.  Genetic Features of blaNDM-1-Positive Enterobacteriaceae , 2011, Antimicrobial Agents and Chemotherapy.

[64]  Timothy R. Walsh,et al.  Characterization of a New Metallo-β-Lactamase Gene, blaNDM-1, and a Novel Erythromycin Esterase Gene Carried on a Unique Genetic Structure in Klebsiella pneumoniae Sequence Type 14 from India , 2009, Antimicrobial Agents and Chemotherapy.

[65]  G. Araj,et al.  Tigecycline in vitro activity against commonly encountered multidrug-resistant gram-negative pathogens in a Middle Eastern country. , 2008, Diagnostic microbiology and infectious disease.

[66]  Outbreak of carbapenemase-producing (NDM-1 and OXA-48) and colistin-resistant Klebsiella pneumoniae ST307, north-east Germany, 2019 , 2019 .

[67]  A. Shibl,et al.  Characterization of carbapenemases, ESBLs, and plasmid-mediated quinolone determinants in carbapenem-insensitive Escherichia coli and Klebsiella pneumoniae in Riyadh hospitals. , 2018, Journal of infection and public health.

[68]  Y. Çetinkol,et al.  The investigation of oxacillinase/metallo-beta-lactamase genes and clonal analysis in carbapenem-resistant Klebsiella pneumoniae. , 2016, Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive.